Primary Hyperoxaluria Market to Exhibit Substantial Growth Rate During the Forecast Period 2032 – DelveInsight | Key Companies – Oxthera, Dicerna Pharma, Allena Pharma, Biocodex, & Others

Delveinsight Business Research LLP
DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Primary Hyperoxaluria Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Primary Hyperoxaluria market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Primary Hyperoxaluria: An Overview

Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.

Primary Hyperoxaluria Market Key Facts

The total prevalent population of Primary Hyperoxaluria in 7MM was 11,900+ in 2020 which is expected to increase by 2032. However, it is observed that the majority of the cases remain undiagnosed.

The estimates suggest a higher diagnosed prevalence of Primary Hyperoxaluria in the United States with 2,300+ diagnosed cases in 2020 which is expected to increase by 2032.

In 2020, out of total diagnosed prevalent cases in Japan, males and females contributed to around 48 and 33 cases, respectively.

The US accounted for the highest prevalent population of Primary Hyperoxaluria among 7MM in 2020.

Among the European countries, the UK had the highest diagnosed prevalent population of PH with 198 cases, followed by Germany which had diagnosed prevalent population of 171, in 2020. On the other hand, Spain had the lowest diagnosed prevalent population.

Get the PDF Sample of the Report:-

Key Benefits of Primary Hyperoxaluria Market Report

The report provides an in-depth analysis of Primary Hyperoxaluria Market Size and Share till 2032 in the 7MM.

The report will help in developing business strategies by understanding the Primary Hyperoxaluria Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.

It covers Primary Hyperoxaluria current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

The report provides a detailed assessment of the Primary Hyperoxaluria market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Primary Hyperoxaluria Market

Primary Hyperoxaluria market size was found to be USD 19 Million in 2020, which is expected to grow during the forecast period. As per DelveInsight, the increase in the patient pool and the expected entry of emerging therapies will boost the Primary Hyperoxaluria (PH) market in the forecasted period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Hyperoxaluria market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Primary Hyperoxaluria market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Primary Hyperoxaluria Epidemiology

The epidemiology section covers insights about the historical and current Primary Hyperoxaluria patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Primary Hyperoxaluria Epidemiology Segmentation

Total Prevalent Cases of Primary Hyperoxaluria 

Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria

Prevalent Cases of Primary Hyperoxaluria 

Diagnosed Prevalent Cases of Primary Hyperoxaluria

Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria

Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria

Primary Hyperoxaluria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Hyperoxaluria market or expected to get launched in the market during the study period. The analysis covers Primary Hyperoxaluria market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Primary Hyperoxaluria Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Primary Hyperoxaluria Therapeutics Analysis

Companies across the globe are diligently working toward the development of novel treatment therapies for Primary Hyperoxaluria with a considerable amount of success over the years. Currently, several key players are diligently involved in developing therapies. The emerging therapies are expected to launch during the forecast period and are anticipated to transform the treatment dynamics.

Primary Hyperoxaluria key companies:


Dicerna Pharmaceuticals

Allena Pharmaceuticals


And many others.

Primary Hyperoxaluria Therapies covered in the report include:




Nedosiran (DCR-PHXC)

And many more.

Get the sample copy of the report, at:

Table of Content

1. Key Insights

2. Executive Summary 

3. Primary Hyperoxaluria Competitive Intelligence Analysis

4. Primary Hyperoxaluria Market Overview at a Glance

5. Primary Hyperoxaluria Disease Background and Overview

6. Primary Hyperoxaluria Patient Journey

7. Primary Hyperoxaluria Epidemiology and Patient Population

8. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Hyperoxaluria Unmet Needs

10. Key Endpoints of Primary Hyperoxaluria Treatment

11. Primary Hyperoxaluria Marketed Products

12. Primary Hyperoxaluria Emerging Therapies

13. Primary Hyperoxaluria Seven Major Market Analysis

14. Attribute Analysis

15. Primary Hyperoxaluria Market Outlook (7 major markets)

16. Primary Hyperoxaluria Access and Reimbursement Overview

17. KOL Views on the Primary Hyperoxaluria Market.

18. Primary Hyperoxaluria Market Drivers

19. Primary Hyperoxaluria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States